| (Values in U.S. Thousands) | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Avita Medical Ltd (AVMXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Avita Medical Ltd., formed through the merger in February 2008 of Clinical Cell Culture Ltd with Visiomed Group Ltd. The Company develops and distributes products in Regenerative and Respiratory Medicine. It offers tissue-engineered products for the treatment of wound and other skin defects. Its product include, ReCell Autologous Spray-On-Skin, which treats of existing scars created by burns, skin grafts, acne, acute wounds or surgery, and skin discolouration including leucoderma and vitiligo. The Company also manufactures and sells a range of spacers for the paediatric, adolescent and adult market. Its respiratory products include the Funhaler incentive asthma spacer designed for the paediatric market and Breath-A-Tech for adolescents and adults in Australia. The Breath-A-Tech hospital-grade spacer can also be autoclaved in the hospital or clinical setting.